Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E

Selinexor is an FDA approved selective inhibitor of the nuclear export protein exportin-1 (XPO1) and causes specific cancer cell death via nuclear accumulation of tumor suppressor proteins. Design of rational studies for the use of selinexor in combination with other therapeutic agents, such as immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Jack G., Walker, Christopher J., Doyle, Amber DP., Johnson, Peter WM., Forconi, Francesco, Cragg, Mark S., Landesman, Yosef, Khakoo, Salim. I., Blunt, Matthew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672299/
https://www.ncbi.nlm.nih.gov/pubmed/34926302
http://dx.doi.org/10.3389/fonc.2021.785635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672299/
https://www.ncbi.nlm.nih.gov/pubmed/34926302
http://dx.doi.org/10.3389/fonc.2021.785635

Ejemplares similares